Multitarget Fluorescence In Situ Hybridization Assay Detects Transitional Cell Carcinoma in the Majority of Patients with Bladder Cancer and Atypical or Negative Urine Cytology

Skacel, Marek; Fahmy, Mona; Brainard, Jennifer; Pettay, James; Biscotti, Charles V.; Liou, Louis S.; Procop, Gary W.; Jones, J. Stephen; Ulchaker, James; Zippe, Craig D.; Tubbs, Raymond R.

doi:10.1097/01.ju.0000066842.45464.cc

Cited by 272 publications

(168 citation statements)

References 12 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…9,25 Urovysiont FISH is one such molecular test that has been shown to have high sensitivity and specificity for the detection of urothelial carcinoma in urine. 8,14,19,21,26 We recently observed several cases of non-urothelial carcinoma that were Urovysiont FISH-positive. Others have also observed these coincidental overlaps with non-urothelial tumors.…”

Section: Discussionmentioning

confidence: 99%

“…7 The gold standard for diagnosis and surveillance of urothelial carcinoma has traditionally been cystoscopy and urine cytology, however both have limitations. [8][9][10][11][12][13][14] Although urine cytology is excellent for detecting high-grade urothelial carcinoma (sensitivity and specificity 475%), it has a low sensitivity (20-60%) for detecting low-grade tumors. 8,[10][11][12][13][14] The low sensitivity of urine cytology, the invasiveness of cystoscopy and its limited usefulness in detecting flat and inaccessible lesions have prompted increased demand for newer, more sensitive and non-invasive tests for detection of urothelial carcinoma.…”

mentioning

confidence: 99%

“…17,18 Urovysiont FISH has a reported sensitivity of 73-92%, a specificity of 89-96% for urothelial carcinoma detection and several studies have confirmed its usefulness in the diagnosis and surveillance of these tumors. 8,14,[19][20][21][22] The test is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus in malignant urothelial cells that are shed in the urine of persons with urothelial carcinoma. These represent some of the most common chromosomal abnormalities in urothelial carcinoma.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

et al. 2009

View full text Add to dashboard Cite

Urovysiont fluorescence in situ hybridization (FISH) is a sensitive and specific test used to diagnose urothelial carcinoma in urine. It detects aneuploidy of chromosomes 3, 7 and 17, and loss of both 9p21 loci in malignant urothelial cells. We evaluated Urovysiont FISH in non-urothelial carcinoma involving bladder to determine its possible application to their diagnosis and surveillance. Paraffin blocks from 31 non-urothelial bladder carcinomas, 12 pure urothelial carcinomas and 2 urothelial carcinomas with squamous differentiation were tested according to Vysis-Abbot Laboratories' recommended standards. Cases included 15 primary squamous carcinoma, 2 urothelial carcinoma with squamous differentiation, 4 primary adenocarcinoma, 5 colonic, 4 prostatic and 1 cervical adenocarcinoma. Total 60% of squamous, 83% of pure urothelial, 100% of urothelial carcinoma with squamous differentiation and 100% of primary and secondary adenocarcinomas hybridized successfully; 2/10 (11%) squamous carcinomas and 11/14 (79%) primary and secondary adenocarcinomas were Urovysiont FISH-positive with primary adenocarcinomas accounting for 75% (3/4), colonic, 80% (4/5), prostatic, 75% (3/4) and cervical, 100% (1/1) positivity. Total 70% (7/10) of pure urothelial carcinomas and 100% (2/2) of urothelial carcinomas with squamous differentiation were Urovysiont FISH-positive. In conclusion, we found that chromosomal abnormalities tested for by Urovysiont FISH may be seen in non-urothelial carcinomas of bladder. These false-positive results were frequent in primary and secondary adenocarcinoma and rare in squamous carcinoma. This has significant implications for the accurate diagnosis and management of patients with urinary tract cancer. Urovysiont FISH cannot be used to definitively diagnose squamous carcinoma or adenocarcinoma nor can it be used to differentiate the two from urothelial carcinoma. However, it may be useful as a surveillance tool in established primary and secondary bladder adenocarcinoma. Cytopathologists and urologists should correlate Urovysiont FISH results with cytomorphology and clinical information.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Furthermore, abnormalities detectable by FISH may precede the evidence of carcinoma on bladder biopsies. 8,9 FISH has also shown promise in the detection of carcinomas of the breast, lung, and colon. [10][11][12][13] Multiple genetic abnormalities have been reported in Barrett's esophagus-associated adenocarcinoma and its precursors.…”

mentioning

confidence: 99%

Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens

et al. 2004

Self Cite

View full text Add to dashboard Cite

Endoscopic brush cytology is a promising surveillance technique for Barrett's esophagus. Ancillary markers are sought to increase the sensitivity of cytology and allow identification of patients at increased risk for disease progression. To determine if there are specific genetic changes in Barrett's esophagus with associated high-grade dysplasia/intramucosal adenocarcinoma compared to those without dysplasia, we performed fluorescence in situ hybridization (FISH) on cytologic specimens using probes to chromosomes and genomic regions previously described as altered in this disease. We studied archival brush cytology slides from 40 Barrett's esophagus patients: 21 with biopsy-proven high-grade dysplasia/carcinoma and 19 with no dysplasia and a minimum 5 years of negative follow-up. Centromeric enumeration probes (CEP) for chromosomes 6, 7, 11, and 12, and locus-specific probes (LSI) for 9p21 (p16 gene), and 17p13.1 (p53 gene) loci along with their corresponding CEP (9 and 17, respectively) were used in this study. A positive FISH result was defined as the presence of cells with 42 CEP signals or with a loss of the LSI signals relative to their corresponding CEP. p53 locus loss and/or aneusomy of chromosomes 6, 7, 11, and 12 abnormalities could be detected by FISH in routinely processed endoscopic brush cytology specimens from 95% of biopsy-positive cases with a specificity of 100%. Interestingly, all five cases with cytologic changes classified as indefinite for dysplasia from patients with a positive biopsy showed changes by FISH. Loss of the p16 locus was seen commonly in patients both with and without dysplasia/carcinoma. Selected biomarkers from this study merit further investigation to determine their potential to detect genetic changes in patients with Barrett's esophagus prior to the development of high-grade dysplasia.

show abstract

“…Several comparative studies have demonstrated that the sensitivity of FISH is superior to that of Cytology alone. [28][29][30] Epilogue According to published reports, the happy couple has settled into a mutually satisfying relationship, each helping to complete the other. The future holds additional opportunities for spousal collaboration: many genetic events, originally identified in hematologic and mesenchymal lesions, are being discovered in a variety of carcinomas as well, particularly salivary gland carcinomas.…”

Section: Bladder Cancermentioning

confidence: 99%

The marriage of Cytology and Cytogenetics

Cin¹,

Qian²,

Cibas³

2013

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

Multitarget Fluorescence In Situ Hybridization Assay Detects Transitional Cell Carcinoma in the Majority of Patients with Bladder Cancer and Atypical or Negative Urine Cytology

Abstract: The UroVysion FISH assay provides high sensitivity and specificity to detect transitional cell carcinoma in cytologically equivocal and negative urine samples. These results emphasize the important role of this assay in the management of bladder cancer.

Cited by 272 publications

References 12 publications

The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens

The marriage of Cytology and Cytogenetics

Contact Info

Product

Resources

About